Cargando…

Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice

BACKGROUND: Oxidative stress and inflammatory reaction play critical roles in acute myocardial infarction (AMI). Isoliquiritigenin (ISL), a flavonoid monomer extracted from licorice, has been found to have antioxidant and anti-inflammatory effects in cancer studies. Here, we tested the effect and un...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Deshan, Shi, Bo, Wang, Sichuan, Bao, Liuxiang, Tan, Meng, Shen, Hui, Zhang, Zhengang, Pan, Xin, Yang, Yi, Wu, Yong, Gong, Kaizheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064455/
https://www.ncbi.nlm.nih.gov/pubmed/35517984
http://dx.doi.org/10.2147/DDDT.S362754
_version_ 1784699380872249344
author Yao, Deshan
Shi, Bo
Wang, Sichuan
Bao, Liuxiang
Tan, Meng
Shen, Hui
Zhang, Zhengang
Pan, Xin
Yang, Yi
Wu, Yong
Gong, Kaizheng
author_facet Yao, Deshan
Shi, Bo
Wang, Sichuan
Bao, Liuxiang
Tan, Meng
Shen, Hui
Zhang, Zhengang
Pan, Xin
Yang, Yi
Wu, Yong
Gong, Kaizheng
author_sort Yao, Deshan
collection PubMed
description BACKGROUND: Oxidative stress and inflammatory reaction play critical roles in acute myocardial infarction (AMI). Isoliquiritigenin (ISL), a flavonoid monomer extracted from licorice, has been found to have antioxidant and anti-inflammatory effects in cancer studies. Here, we tested the effect and underlying mechanisms of ISL on ischemia-induced myocardial injury in a mouse AMI model. METHODS: Adult C57BL/6 mice were pre-treated by intraperitoneal injection of ISL and/or a specific nuclear factor E2-related factor 2 (Nrf2) inhibitor ML385 for 3 days, respectively. Then, the AMI model was established by ligating the anterior descending branch of the left coronary artery. Myocardial oxidative stress status, inflammatory response, cardiac function and infarction size were assessed after 7th day of surgery. RESULTS: Compared with sham group, the reactive oxygen species (ROS) and malondialdehyde (MDA) level in AMI group were significantly increased. However, the superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) level were dramatically decreased. ISL treatment significantly reduced the myocardial infarction area, improved cardiac function, inhibited the production of ROS and MDA and reduced the consumption of SOD and GSH-Px. Interestingly, ISL could significantly increase nuclear Nrf2 and cytosolic heme oxygenase 1 (HO-1) level in the infarcted myocardium and reduce the oxidative stress after AMI. Also, ISL treatment dramatically inhibited the activation of myocardial NF-κB pathway and reduced the expression of pro-inflammatory factors in the AMI group. However, the administration of ML385 not only suppressed the Nrf2/HO-1 activation, the anti-oxidant and anti-inflammatory effects induced by ISL, but also attenuated the beneficial role of ISL on reducing infarct size and improving cardiac function in the mouse with AMI. CONCLUSION: The results suggested that activation of Nrf2/HO-1 pathway has an essential role in ISL-induced cardiac protection by alleviating myocardial oxidative stress and inflammation response in mice with AMI.
format Online
Article
Text
id pubmed-9064455
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90644552022-05-04 Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice Yao, Deshan Shi, Bo Wang, Sichuan Bao, Liuxiang Tan, Meng Shen, Hui Zhang, Zhengang Pan, Xin Yang, Yi Wu, Yong Gong, Kaizheng Drug Des Devel Ther Original Research BACKGROUND: Oxidative stress and inflammatory reaction play critical roles in acute myocardial infarction (AMI). Isoliquiritigenin (ISL), a flavonoid monomer extracted from licorice, has been found to have antioxidant and anti-inflammatory effects in cancer studies. Here, we tested the effect and underlying mechanisms of ISL on ischemia-induced myocardial injury in a mouse AMI model. METHODS: Adult C57BL/6 mice were pre-treated by intraperitoneal injection of ISL and/or a specific nuclear factor E2-related factor 2 (Nrf2) inhibitor ML385 for 3 days, respectively. Then, the AMI model was established by ligating the anterior descending branch of the left coronary artery. Myocardial oxidative stress status, inflammatory response, cardiac function and infarction size were assessed after 7th day of surgery. RESULTS: Compared with sham group, the reactive oxygen species (ROS) and malondialdehyde (MDA) level in AMI group were significantly increased. However, the superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) level were dramatically decreased. ISL treatment significantly reduced the myocardial infarction area, improved cardiac function, inhibited the production of ROS and MDA and reduced the consumption of SOD and GSH-Px. Interestingly, ISL could significantly increase nuclear Nrf2 and cytosolic heme oxygenase 1 (HO-1) level in the infarcted myocardium and reduce the oxidative stress after AMI. Also, ISL treatment dramatically inhibited the activation of myocardial NF-κB pathway and reduced the expression of pro-inflammatory factors in the AMI group. However, the administration of ML385 not only suppressed the Nrf2/HO-1 activation, the anti-oxidant and anti-inflammatory effects induced by ISL, but also attenuated the beneficial role of ISL on reducing infarct size and improving cardiac function in the mouse with AMI. CONCLUSION: The results suggested that activation of Nrf2/HO-1 pathway has an essential role in ISL-induced cardiac protection by alleviating myocardial oxidative stress and inflammation response in mice with AMI. Dove 2022-04-29 /pmc/articles/PMC9064455/ /pubmed/35517984 http://dx.doi.org/10.2147/DDDT.S362754 Text en © 2022 Yao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yao, Deshan
Shi, Bo
Wang, Sichuan
Bao, Liuxiang
Tan, Meng
Shen, Hui
Zhang, Zhengang
Pan, Xin
Yang, Yi
Wu, Yong
Gong, Kaizheng
Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice
title Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice
title_full Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice
title_fullStr Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice
title_full_unstemmed Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice
title_short Isoliquiritigenin Ameliorates Ischemia-Induced Myocardial Injury via Modulating the Nrf2/HO-1 Pathway in Mice
title_sort isoliquiritigenin ameliorates ischemia-induced myocardial injury via modulating the nrf2/ho-1 pathway in mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064455/
https://www.ncbi.nlm.nih.gov/pubmed/35517984
http://dx.doi.org/10.2147/DDDT.S362754
work_keys_str_mv AT yaodeshan isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT shibo isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT wangsichuan isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT baoliuxiang isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT tanmeng isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT shenhui isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT zhangzhengang isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT panxin isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT yangyi isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT wuyong isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice
AT gongkaizheng isoliquiritigeninamelioratesischemiainducedmyocardialinjuryviamodulatingthenrf2ho1pathwayinmice